Obsidian Therapeutics and Galera Therapeutics Merge in $350 Million Funded Transaction

Werewolf Therapeutics and Ambros Therapeutics Merge in $150M PIPE to Advance Neridronate Phase 3

August 23, 2026

Pharmaceuticals

Werewolf Therapeutics and Ambros Therapeutics entered into a definitive all-stock merger agreement, with a concurrently announced, oversubscribed $150 million private placement expected to fund development of neridronate through pivotal Phase III results and a planned FDA submission. The combined company will operate as Ambros Therapeutics, be headquartered in San Diego, and is expected to trade on Nasdaq as AMBX.

Synlogic and Caldera Therapeutics Announce Definitive Merger Agreement

July 29, 2026

Healthcare Services

Synlogic and Caldera Therapeutics entered into a definitive all-stock merger agreement to combine into a newly formed holding company, with the combined company operating as Caldera Therapeutics, Inc. The transaction is expected to close in early 2027 and includes a concurrent upsized private placement expected to generate approximately $278 million to fund Phase 2 development of CLD-423.

Korsana Biosciences Merges with Cyclerion Therapeutics

April 1, 2026

Biotechnology

Korsana Biosciences and Cyclerion Therapeutics entered into an all-stock merger agreement, with the combined company to operate as Korsana Biosciences and focus on advancing Korsana’s neurodegenerative disease pipeline. The merger was completed on September 8, 2026; a concurrent $380 million private placement was completed immediately before closing to fund operations and clinical milestones.

Visiox Pharmaceuticals Announces Definitive Merger With Ocuvex Therapeutics

August 19, 2024

Healthcare Services

Visiox Pharmaceuticals, Inc. entered into a definitive merger agreement with Ocuvex Therapeutics, Inc., an ophthalmic pharmaceutical company focused on developing and commercializing therapies for glaucoma and other eye disorders. The combined company will operate under the Ocuvex name, aiming to strengthen its ophthalmic portfolio and accelerate commercialization of near-term products.

Gilead Sciences Acquires XinThera

May 9, 2023

Biotechnology

Gilead Sciences has acquired all outstanding shares of XinThera, a San Diego–based private biotechnology company, adding small-molecule oncology and inflammation programs (including PARP1-selective and MK2-targeting assets) to its early pipeline. Financial terms were not disclosed; XinThera was backed by investors including Foresite Capital, OrbiMed and TTM Capital.

Gemini Therapeutics and Disc Medicine Announce Definitive Merger Agreement

August 10, 2022

Healthcare Services

Gemini Therapeutics (Gemini) and Disc Medicine (Disc) entered into a definitive, all-stock merger agreement to combine the companies into a NASDAQ-listed, clinical-stage biopharmaceutical focused on advancing Disc’s hematology pipeline. The merged company is expected to have about $175 million in cash at closing, including $53.5 million from a concurrent financing led by Access Biotechnology and including OrbiMed and other healthcare investors, with the merger expected to close in Q4 2022.